Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion)Proposed acquisition expected to be immediately accretive to sales growth and EBITDA pre margin post-closing, and EPS pre accretive by year 3 after closingU.S.-based Bio-Techne to bring…
News provided by PR Newswire.
